Institute of Health and
Biomedical Innovation
a university for the real world

Research areas

IHBI is an interdisciplinary research organisation offering an entrepreneurial environment which combines the strengths of QUT’s Faculties of Health, and Science and Engineering.

IHBI engages researchers in large scale programmatic activities allowing research to be undertaken at scale to address current and future global challenges. IHBI’s researchers focus on three broad areas: prevention, intervention, and translation, with significant strength in biomedical technologies, genomics and precision medicine and cancer research. In addition to its location at Kelvin Grove, IHBI has a number of key distributed sites at the Translational Research Institute (TRI), the Children’s Health Research Centre (CCHR), QIMR-Berghofer and a Medical Engineering Research Facility (MERF) at The Prince Charles Hospital.

IHBI draws from a wide base of leading health and biomedical researchers including engineers, physicians, molecular biologists, geneticists, nurses, psychologists, public health experts, vision scientists, movement physiologists and statisticians. IHBI has ongoing links with local and interstate hospitals, health care service providers, medical researchers worldwide, clinical specialists and industry professionals. IHBI also benefits from QUT’s highly successful track record in commercial partnerships and sustainable biotech companies.

IHBI’s vision is to create an open, collaborative environment fostering real biomedical and health science innovation and excellence. Commercialisation goals are to develop specific products and services that are highly competitive in the international market place and have significant health benefit outcomes. Social impact goals include community, education, implementation of health innovations and partnerships.

IHBI successes include:

  • Focusing on early intervention to address poor health trajectories in childhood and arrest high rates of chronic disease, including in Indigenous communities
  • Understanding the needs of patients, their carers, clinicians and industry as part of clinical trials in cancer and neurological disease
  • Contributing significantly to providing better health through screening patient samples for cancer-causing genetic mutations at the Australian Translational Genomics Centre
  • Providing input in designing and developing medical devices, such an implants, to improve outcomes and minimise complications
  • Working with clinicians and using computer modelling for pre-operative planning to improve outcomes for people with orthopaedic disorders
  • Securing support and establishing collaborations focused on training the future workforce and building an entrepreneurial mindset among scientists.

IHBI’s future focus involves:

  • Continuing multi-dimensional research, such as work across genetics, laboratory modelling and clinical trials conducted at the Centre for Personalised Analysis of Cancers at the Translational Research Institute
  • Using the latest technology and pairing it with relevant expertise to gain new understanding of tissue, such as tumour cells and immune cell interactions, needed for immunotherapeutic medicines
  • Combining robotics, artificial intelligence and advanced manufacturing to expand surgical possibilities and improve treatment of complex medical cases
  • Bringing medicine together with physics, engineering and the humanities to create a future for healthcare that is better and fairer.